TSA (Trichostatin A)
中文名称:曲古抑菌素A
目录号:S1045 Purity: 99.94%
TSA (Trichostatin A) 是一种HDAC抑制剂,无细胞试验中IC50为1.8 nM左右。
CAS: 58880-19-6
客户使用Selleck的TSA (Trichostatin A)发表文献277篇
- Cell Discov, 2023 9(1):85
- Cell Res, 2022 10.1038/s41422-022-00668-0
- Nat Neurosci, 2022 25(5):596-606
- Cell Stem Cell, 2022 S1934-5909(22)00010-8
- Nature, 2021 10.1038/s41586-021-04116-8
- Signal Transduct Target Ther, 2021 6(1):333
- Nat Metab, 2021 3(1):75-89
- Signal Transduct Target Ther, 2020 13;5(1):53
- Cell, 2019 178(5):1115-1131
- Cell Metab, 2019 29(4):886-900
- Nat Biomed Eng, 2018 2(8):578-588
- Nature, 2017 551(7679):247-250
- Cell, 2017 171(4):824-835.e18
- Cell Res, 2017 27(7):898-915
- Cell Mol Immunol, 2017 14(4):371-379
- Nat Biotechnol, 2015 10.1038/nbt.3130
- Science, 2014 344(6183):1252304
- Cancer Cell, 2014 26(4):534-48
- Nat Commun, 2024 15(1):1190
- Nat Commun, 2024 15(1):5209
- Nat Commun, 2024 15(1):9463
- Nucleic Acids Res, 2024 gkae721
- Plant Biotechnol J, 2024 10.1111/pbi.14299
- Dev Cell, 2024 S1534-5807(24)00326-5
- Redox Biol, 2024 73:103184
- EBioMedicine, 2024 105:105211
- Int J Biol Sci, 2024 20(6):2202-2218
- Cell Rep, 2024 43(2):113779
- Cell Rep, 2024 43(9):114642
- Br J Cancer, 2024 10.1038/s41416-024-02636-4
- Elife, 2024 12RP86978
- EMBO Rep, 2024 10.1038/s44319-024-00343-y
- Mol Oncol, 2024 18(9):2314-2330
- Commun Biol, 2024 7(1):1365
- J Genet Genomics, 2024 S1673-8527(24)00192-9
- J Leukoc Biol, 2024 qiae006
- Pharmaceutics, 2024 16(1)126
- J Biol Chem, 2024 300(8):107554
- Sci Adv, 2024 10(44):eadp0631
- Nat Commun, 2023 14(1):5917
- Nat Commun, 2023 14(1):2095
- Exp Mol Med, 2023 55(10):2205-2219
- Cell Rep, 2023 42(7):112770
- Cell Rep, 2023 42(8):112869
- Cell Rep, 2023 42(2):112041
- J Cell Biol, 2023 222(5)e202201068
- Elife, 2023 12e85412
- J Transl Med, 2023 10.1186/s12967-023-04623-4
- Mol Cell Proteomics, 2023 22(3):100504
- Clin Epigenetics, 2023 15(1):19
- Int J Mol Sci, 2023 24(15)11899
- Biomolecules, 2023 13(9)1324
- Viruses, 2023 15(9)1874
- Cancer Manag Res, 2023 15:1165-1179
- Shock, 2023 60(1):75-83
- J Cardiovasc Pharmacol, 2023 81(2):150-164
- Sci Adv, 2023 9(22):eadg4993
- Surg Open Sci, 2023 12:35-42
- Nat Commun, 2022 13(1):7759
- Nucleic Acids Res, 2022 50(17):9873-9892
- J Immunother Cancer, 2022 10(3)e003477
- Sci Total Environ, 2022 838(Pt 1):155713
- Cell Death Dis, 2022 13(6):530
- Cell Rep, 2022 39(12):110994
- Cell Rep, 2022 38(7):110390
- Cell Rep, 2022 40(3):111088
- Cell Rep, 2022 40(2):111062
- Cell Rep, 2022 40(3):111116
- NPJ Precis Oncol, 2022 6(1):75
- Cell Biosci, 2022 12(1):135
- Plant Physiol, 2022 kiac015
- Cell Death Discov, 2022 8(1):474
- PLoS Pathog, 2022 18(5):e1010505
- Expert Opin Ther Pat, 2022 32(9):969-1001
- iScience, 2022 25(10):105182
- Clin Epigenetics, 2022 14(1):147
- Int J Mol Sci, 2022 23(18)10791
- Front Pharmacol, 2022 13:797469
- Pharmaceutics, 2022 14(7)1420
- Oncotarget, 2022 13:1122-1135
- Cancers (Basel), 2022 14(8)1897
- J Cancer, 2022 13(6):1734-1744
- Brain Res Bull, 2022 184:24-33
- Am J Transl Res, 2022 14(6):3840-3853
- Sci Adv, 2022 8(31):eabo0412
- Nat Commun, 2021 12(1):7213
- Nat Commun, 2021 12(1):4404
- Mol Cell, 2021 S1097-2765(21)00051-4
- Hepatology, 2021 10.1002/hep.32245
- Theranostics, 2021 11(8):3760-3780
- Gut Microbes, 2021 13(1):1968257
- Proc Natl Acad Sci U S A, 2021 118(22)e2014681118
- Cancer Lett, 2021 513:36-49
- Sci China Life Sci, 2021 10.1007/s11427-020-1855-4
- Cell Death Dis, 2021 12(6):532
- Cell Death Dis, 2021 12(4):405
- Cell Death Dis, 2021 12(9):820
- Cell Rep, 2021 37(3):109857
- Cell Rep, 2021 34(3):108646
- J Pathol, 2021 10.1002/path.5657
- Clin Epigenetics, 2021 13(1):187
- Front Cell Dev Biol, 2021 9:719720
- Front Cell Dev Biol, 2021 9:741736
- Front Endocrinol (Lausanne), 2021 12:573824
- Cancers (Basel), 2021 13(15)3821
- Neoplasia, 2021 23(1):129-139
- Front Oncol, 2021 11:746266
- Front Oncol, 2021 11:773644
- J Inflamm Res, 2021 14:5849-5862
- Mol Cell Biochem, 2021 10.1007/s11010-021-04050-3
- PLoS One, 2021 16(11):e0260633
- Retrovirology, 2021 18(1):38
- G3 (Bethesda), 2021 11(10)jkab265
- Sci Adv, 2021 7(9)eabe5518
- Neuroreport, 2021 32(12):1049-1057
- Autophagy, 2020 10.1080/15548627.2019.1709762
- Autophagy, 2020 15:1-13
- Theranostics, 2020 10(17):7747-7757
- Theranostics, 2020 10(21):9644-9662
- Theranostics, 2020 10(15):6790-6805
- Theranostics, 2020 10(5):2188-2200
- Cell Death Dis, 2020 11(9):765
- Cell Rep, 2020 30(7):2195-2208
- Cell Rep, 2020 33(11):108507
- Free Radic Biol Med, 2020 10.1016/j.freeradbiomed.2020.01.016
- Front Immunol, 2020 3;11:36
- mBio, 2020 11(5)e02343-20
- Oncogenesis, 2020 13;9(5):48
- Cells, 2020 21;9(5):E1280
- Mol Cancer Ther, 2020 molcanther.0417.2020
- Cancer Biol Med, 2020 17(4):953-969
- Front Chem, 2020 23;8:184
- Am J Cancer Res, 2020 10(2):523-535
- Mol Cancer Res, 2020 18(7):1004-1017
- Mol Neurobiol, 2020 10.1007/s12035-019-01812-5
- BMC Microbiol, 2020 20(1):28
- ACS Med Chem Lett, 2020 11(10):1886-1892
- J Immunol Res, 2020 2020:7263602
- Immunol Cell Biol, 2020 98(4):318-331
- Arch Insect Biochem Physiol, 2020 103(4):e21649
- Nat Commun, 2019 10(1):5792
- Nat Commun, 2019 10(1):4353
- Nat Commun, 2019 10(1):5800
- Mol Cell, 2019 74(6):1250-1263
- Mol Cell, 2019 73(4):788-802
- Nucleic Acids Res, 2019 19;47(16):8502-8520
- Autophagy, 2019 1-13
- Autophagy, 2019 10.1080/15548627.2019.1707488
- Mol Ther, 2019 27(5):1039-1050
- Cell Death Differ, 2019 26(5):843-859
- J Exp Clin Cancer Res, 2019 38(1):428
- J Exp Clin Cancer Res, 2019 38(1):84
- J Exp Clin Cancer Res, 2019 38(1):463
- Cancer Res, 2019 10.1158/0008-5472.CAN-18-2486
- EBioMedicine, 2019 43:238-252
- PLoS Biol, 2019 17(10):e3000461
- Pharmacol Res, 2019 146:104281
- J Cell Biol, 2019 218(1):267-284
- J Cell Biol, 2019 218(12):4017-4029
- Int J Cancer, 2019 10.1002/ijc.32425
- J Bone Miner Res, 2019 10.1002/jbmr.3716
- Life Sci, 2019 223:1-8
- Cancer Sci, 2019 110(11):3442-3452
- Mol Cancer Ther, 2019 18(5):900-908
- J Mol Cell Biol, 2019 10.1093/jmcb/mjz093
- Int J Mol Med, 2019 44(5):1789-1800
- Int J Mol Med, 2019 43(1):285-293
- J Virol, 2019 93(4)e01896-18
- Front Cell Neurosci, 2019 13:468
- Mol Neurobiol, 2019 10.1007/s12035-019-1565-7
- J Mol Med (Berl), 2019 97(4):541-552
- J Neurochem, 2019 10.1111/jnc.14935
- Sci Rep, 2019 9(1):1897
- Sci Rep, 2019 9(1):4360
- PLoS Comput Biol, 2019 15(2):e1006826
- Oncol Rep, 2019 41(6):3209-3218
- ACS Omega, 2019 4(22):19895-19904
- J Cell Biochem, 2019 10.1002/jcb.29470
- Front Genet, 2019 10:422
- Alcohol Clin Exp Res, 2019 43(5):822-832
- Tuberculosis (Edinb), 2019 118:101861
- Cell Adh Migr, 2019 13(1):285-292
- Exp Ther Med, 2019 17(6):4547-4553
- Res Vet Sci, 2019 126:207-212
- Reprod Fertil Dev, 2019 31(3):473-481
- Sci Adv, 2019 5(3):eaav1118
- bioRxiv, 2019 10.1101/748129
- J Clin Invest, 2018 128(9):4098-4114
- Mol Ther, 2018 26(7):1828-1839
- Cancer Res, 2018 78(20):5731-5740
- Cancer Lett, 2018 432:121-131
- Cell Rep, 2018 24(7):1722-1729
- Oncogene, 2018 37(8):1049-1061
- Oncogene, 2018 37(50):6414-6424
- Mol Oncol, 2018 12(5):724-755
- Oncogenesis, 2018 7(11):91
- Plant Cell Rep, 2018 37(1):115-123
- Int Immunopharmacol, 2018 65:303-311
- Sci Rep, 2018 8(1):8492
- Sci Rep, 2018 8(1):13072
- J Proteome Res, 2018 17(4):1436-1451
- Oncol Rep, 2018 39(4):1892-1900
- Exp Cell Res, 2018 371(1):231-237
- Cell Biochem Funct, 2018 36(8):398-407
- Med Sci Monit, 2018 24:461-472
- Biochem Biophys Res Commun, 2018 503(2):420-427
- Curr Protoc Pharmacol, 2018 81(1):e41
- Methods Mol Biol, 2018 1755:179-195
- Mol Cell, 2017 67(4):566-578
- Oncogene, 2017 36(12):1707-1720
- Plant Physiol, 2017 175(3):1484-1496
- Eur J Med Chem, 2017 127:531-553
- Oncotarget, 2017 8(11):17995-18009
- Oncotarget, 2017 8(7):11937-11949
- J Biol Chem, 2017 292(31):12842-12859
- Sci Rep, 2017 7:46195
- Chemistry, 2017 23(13):3107-3116
- J Diabetes Res, 2017 2017:8208065
- Int J Parasitol Drugs Drug Resist, 2017 7(1):51-60
- Cancer Epidemiol Biomarkers Prev, 2017 26(9):1411-1419
- PLoS One, 2017 12(10):e0186620
- J Pharmacol Exp Ther, 2017 363(2):211-220
- Bioorg Med Chem, 2017 25(7):2105-2132
- Biochem Biophys Res Commun, 2017 485(2):454-460
- Connect Tissue Res, 2017 58(1):64-75
- Nat Commun, 2016 7:10690
- Nucleic Acids Res, 2016 45(3):1159-1176
- Clin Cancer Res, 2016 22(8):1978-88
- Thorax, 2016 633-45
- EMBO Rep, 2016 17(7):999-1012
- Free Radic Biol Med, 2016 99:167-178
- Oxid Med Cell Longev, 2016 2016:4085727
- J Med Chem, 2016 59(4):1613-33
- PLoS Pathog, 2016 12(10):e1005950
- Am J Pathol, 2016 186(10):2701-8
- FEBS J, 2016 283(20):3739-3754
- Oncotarget, 2016 8(60):100975-100988
- Mol Cell Biol, 2016 36(22):2838-2854
- Int J Oncol, 2016 48(6):2591-607
- Sci Rep, 2016 6:21678
- Mol Cell Biochem, 2016 415(1-2):197-205
- BMC Cancer, 2016 16(1):886
- Genet Mol Res, 2016 15(4)
- Tumour Biol, 2016 37(6):8293-304
- Tumour Biol, 2016 37(8):10269-78
- Nat Commun, 2015 3;6:10091
- EMBO Mol Med, 2015 10.15252/emmm.201404396
- Cancer Lett, 2015 356(2 Pt B):828-36
- Cell Death Dis, 2015 6:e1586
- Am J Transplant, 2015 10.1111/ajt.13106
- Oncotarget, 2015 6(18):15814-27
- Mol Nutr Food Res, 2015 59(2):189-202
- J Antimicrob Chemother, 2015 10.1093/jac/dku549
- Chem Biol Interact, 2015 242:227-34
- Am J Physiol Lung Cell Mol Physiol, 2015 309(12):L1410-9
- PLoS One, 2015 10(3):e0120587
- J Appl Physiol (1985), 2015 119(4):342-51
- EMBO J, 2014 34(1):115-29
- Proc Natl Acad Sci USA, 2014 111(3):E364-73
- PLoS Biol, 2014 12(1):e1001758
- Cancer Lett, 2014 10.1016/j.canlet.2014.10.034
- Life Sci, 2014 99(1-2):31-6
- Oncotarget, 2014 5(16):6701-15
- Mol Cell Biol, 2014 34(22):4143-64
- Development, 2014 141(7):1534-43
- Sci Rep, 2014 4:4663
- Cell Cycle, 2014 13(23):3759-67
- Toxicol Appl Pharmacol, 2014 274(1):7-16
- Biochem Biophys Res Commun, 2014 445(2):320-6
- Exp Hematol, 2014 42(7):574-80
- Methods Mol Biol, 2014 1156:431-43
- Neuropsychopharmacology, 2013 38(9):1674-84
- Plant J, 2013 74(5):815-28
- Cytokine, 2013 65(2):121-5
- Genes Brain Behav, 2013 13(1):69-86
- Epigenetics, 2012 7(10):1161-72
- Adv Genet, 2010 70:341-86
化学信息&溶解度
分子量 | 302.4 |
分子式 | C17H22N2O3 |
CAS号 | 58880-19-6 |
Smiles | CC(C=C(C)C=CC(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 60 mg/mL ( 198.41 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble DMSO : 60 mg/mL ( 198.41 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
2%DMSO
30%PEG300
2%Tween80
66%ddH2O
浓度:1.5mg/ml
(4.96mM)
操作示例:以 1 mL 工作液为例,取20μL75mg/ml的澄清DMSO储备液加到300μL PEG300中,混合均匀使其澄清;向上述体系中加入20μLTween80,混合均匀使其澄清;然后继续加入660μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。